Detailed description of the market in oncological conditions
DETAILED DESCRIPTION OF THE MARKET IN ONCOLOGICAL CONDITIONS THERAPEUTIC REGIMENS USED, PATIENT PROFILE THE CLIENT’S BUSINESS OBJECTIVE:Provide all interested market […]
Economedica – determination of patient population
ECONOMEDICA – DETERMINATION OF PATIENT POPULATION EPIDEMIOLOGICAL STUDIES, CALCULATION OF INDIRECT COSTS CLIENT’S BUSINESS OBJECTIVE:The Client planned to market an
Patients pathway to appropriate treatment – barriers to diagnosis and integration of treatment
PATIENT’S PATHWAY TO APPROPRIATE TREATMENT – BARRIERS TO DIAGNOSIS AND INTEGRATION OF TREATMENT PATIENT PATHWAY CLIENT BUSINESS OBJECTIVE:To diagnose the
Who has patients under their care with a rare disease for which there has been no dedicated treatment to date
WHO HAS PATIENTS UNDER THEIR CARE WITH A RARE DISEASE FOR WHICH THERE HAS BEEN NO DEDICATED TREATMENT TO DATE?
MASTER OF POLISH DRUG POLICY FOR PEX TEAM
MASTER OF POLISH DRUG POLICY FOR PEX TEAM Dear Sirs, We are happy to announce that the PEX Team has
LIST OF 100 2023: HEALTH SYSTEM
LIST OF 100 2023: HEALTH SYSTEM Dear Sirs, We are happy to announce that PEX CEO dr Jarek Frąckowiak, representing
INFORMATION ABOUT THE INTEGRATION TRIP OF THE PEX TEAM ON JUNE 10-12
INFORMATION ABOUT THE INTEGRATION TRIP OF THE PEX TEAMON JUNE 10-12 Dear Sirs, On June 10-12, our team will be on a team-building trip. During this time,
EASTER GREETINGS
EASTER GREETINGS Dear Sirs, On behalf of the PEX Team and myself, I extend my warmest wishes to you for
NOTICE OF CHANGE OF NAME OF COMPANY PEX PHARMASEQUENCE TO PEX
NOTICE OF CHANGE OF NAME OF COMPANY PEX PHARMASEQUENCE TO PEX Dear Sirs, We are pleased to announce the change/upgrade